title: [Prophylactic recombinant human thrombopoietin treatment alleviates chemotherapy- induced thrombocytopenia in tumor patients].
abstract: OBJECTIVE
  To assess the efficacy of prophylactic treatment with recombinant human thrombopoietin (rhTPO) on chemotherapy-induced thrombocytopenia in tumor patients.
  
  
  METHODS
  In this randomized cross-over self-controlled clinical trial, 24 patients with malignant neoplasms were randomized group A (12 cases) and group B (12 cases). All the patients underwent two identical cycles of chemotherapy. In group A, RhTPO (1.0 µg/kg) was administered subcutaneously on a daily basis 3 days before the second chemotherapy cycle for 7 consecutive days, and in group B, RhTPO was administered daily 6-24 h after the second chemotherapy cycle for 7 days. In both groups, RhTPO was not administered in the first chemotherapy cycle, which served as the control cycle.
  
  
  RESULTS
  In both the groups, platelet count was significantly higher in the second cycle than in the control cycle, and the duration of thrombocytopenia was significantly shortened in the second cycle. Compared with group B, the patients in group A showed a significantly higher platelet count in the second cycle and a significantly shorter duration of thrombocytopenia in the second cycle.
  
  
  CONCLUSIONS
  Prophylactic administration of rhTPO can significantly reduce the severity and duration of thrombocytopenia and promote platelet recovery in patients undergoing chemotherapy for malignant tumors.
authors: Department of Oncology, First Affiliated Hospital of General Hospital of PLA, Beijing 100048, China. lyq2001@tom.com
authors: Qiuwen
authors: Q
authors: Li
authors: Ming
authors: M
authors: Ye
authors: Wenhua
authors: W
authors: Xiao
authors: Jianhua
authors: J
authors: Zhu
authors: Shufang
authors: S
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*; D013926:Thrombopoietin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D013926:Thrombopoietin